Complete financial analysis of Alphatec Holdings, Inc. (ATEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alphatec Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Reliability Incorporated (RLBY) Income Statement Analysis – Financial Results
- Sinomach Precision Industry Co.,Ltd. (002046.SZ) Income Statement Analysis – Financial Results
- Chi Cheng Enterprise Co., Ltd. (3095.TWO) Income Statement Analysis – Financial Results
- Abingdon Health Plc (ABDXF) Income Statement Analysis – Financial Results
- Drone Volt SA (ALDRV.PA) Income Statement Analysis – Financial Results
Alphatec Holdings, Inc. (ATEC)
About Alphatec Holdings, Inc.
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 482.26M | 350.87M | 243.21M | 144.86M | 113.43M | 91.69M | 101.74M | 120.25M | 185.28M | 206.98M | 204.72M | 196.28M | 197.71M | 171.61M | 132.16M | 101.31M | 80.03M | 74.01M | 42.33M | 17.82M | 10.89M | 11.34M | 13.96M |
| Cost of Revenue | 172.06M | 117.81M | 85.45M | 42.36M | 35.83M | 28.46M | 39.41M | 44.11M | 63.74M | 61.83M | 78.67M | 70.76M | 80.78M | 58.79M | 48.02M | 36.61M | 29.82M | 25.70M | 17.72M | 5.46M | 0.00 | 4.50M | 5.85M |
| Gross Profit | 310.20M | 233.06M | 157.76M | 102.50M | 77.59M | 63.24M | 62.33M | 76.13M | 121.54M | 145.15M | 126.06M | 125.52M | 116.93M | 112.82M | 84.14M | 64.71M | 50.21M | 48.31M | 24.60M | 12.36M | 10.89M | 6.84M | 8.12M |
| Gross Profit Ratio | 64.32% | 66.42% | 64.87% | 70.76% | 68.41% | 68.97% | 61.27% | 63.31% | 65.60% | 70.13% | 61.57% | 63.95% | 59.14% | 65.74% | 63.67% | 63.87% | 62.73% | 65.27% | 58.13% | 69.36% | 100.00% | 60.32% | 58.13% |
| Research & Development | 70.12M | 44.03M | 32.02M | 18.75M | 13.85M | 9.98M | 4.92M | 9.25M | 18.04M | 17.33M | 14.19M | 15.23M | 16.89M | 19.40M | 13.49M | 12.97M | 6.36M | 3.59M | 4.07M | 1.18M | 0.00 | 415.00K | 326.15K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.22M | 26.34M | 34.87M | 43.38M | 47.95M | 39.94M | 36.37M | 34.75M | 22.32M | 23.36M | 54.19M | 66.83M | 35.58M | 11.01M | 0.00 | 7.22M | 7.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.51M | 41.16M | 50.96M | 70.86M | 77.18M | 76.96M | 75.18M | 75.19M | 66.54M | 51.51M | 42.44M | 29.94M | 33.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 374.08M | 300.01M | 229.27M | 129.16M | 101.71M | 72.51M | 64.38M | 77.30M | 105.72M | 120.56M | 124.91M | 115.12M | 111.56M | 101.29M | 73.83M | 65.80M | 54.19M | 66.83M | 35.58M | 11.01M | 0.00 | 7.22M | 7.51M |
| Other Expenses | 39.40M | 10.12M | 5.35M | 688.00K | 698.00K | 738.00K | -133.00K | -715.00K | 6.98M | -33.00K | -1.66M | -794.00K | 2.15M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 483.60M | 354.16M | 266.63M | 148.59M | 116.26M | 83.23M | 69.99M | 87.48M | 127.62M | 142.60M | 143.84M | 134.27M | 130.60M | 122.22M | 87.32M | 89.76M | 60.55M | 70.42M | 39.65M | 12.18M | 0.00 | 7.64M | 7.84M |
| Cost & Expenses | 655.66M | 471.97M | 352.08M | 190.95M | 152.09M | 111.69M | 109.39M | 131.60M | 191.36M | 204.43M | 222.51M | 205.03M | 211.38M | 181.02M | 135.33M | 126.37M | 90.37M | 96.12M | 57.37M | 17.64M | 0.00 | 12.14M | 13.68M |
| Interest Income | 0.00 | 5.51M | 7.11M | 12.37M | 9.87M | 0.00 | 0.00 | 3.00K | 11.00K | 10.00K | 6.00K | 118.00K | 148.00K | 81.00K | 67.00K | 374.00K | 793.00K | 701.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.64M | 5.51M | 7.11M | 12.37M | 0.00 | 7.14M | 7.48M | 15.56M | 5.56M | 13.64M | 5.62M | 6.78M | 3.03M | 4.70M | 3.49M | 1.88M | 868.00K | 2.13M | 1.93M | 311.51K | 0.00 | 240.00K | 0.00 |
| Depreciation & Amortization | 59.68M | 43.93M | 30.17M | 11.63M | 8.51M | 6.79M | 7.48M | 12.36M | 3.85M | 4.71M | 4.74M | 3.93M | 2.15M | 1.54M | 11.96M | 8.73M | 10.62M | 9.02M | 3.54M | 633.85K | 0.00 | 0.00 | 0.00 |
| EBITDA | -110.59M | -102.58M | -106.88M | -54.84M | -48.63M | -13.21M | 136.00K | -13.20M | -149.37M | 20.21M | -48.81M | 10.38M | -3.79M | 6.71M | 2.38M | -18.21M | -8.27M | -13.10M | -11.50M | 1.55M | 10.89M | -798.00K | 277.21K |
| EBITDA Ratio | -22.93% | -31.50% | -43.21% | -31.34% | -25.88% | -21.00% | -0.30% | -8.66% | -1.20% | 3.51% | -6.37% | -2.46% | -0.34% | -4.59% | -2.40% | -22.02% | 11.84% | -14.99% | -26.90% | 0.41% | 100.00% | -7.04% | 1.99% |
| Operating Income | -173.40M | -121.10M | -108.87M | -46.09M | -38.67M | -22.44M | -9.00M | -15.38M | -172.44M | 1.84M | -73.43M | -9.84M | -24.52M | -11.79M | -9.56M | -27.81M | -19.69M | -22.11M | -15.04M | 177.81K | 10.89M | -798.00K | 277.21K |
| Operating Income Ratio | -35.95% | -34.52% | -44.76% | -31.82% | -34.09% | -24.47% | -8.85% | -12.79% | -93.07% | 0.89% | -35.87% | -5.01% | -12.40% | -6.87% | -7.23% | -27.45% | -24.60% | -29.88% | -35.54% | 1.00% | 100.00% | -7.04% | 1.99% |
| Total Other Income/Expenses | -13.52M | -30.91M | -16.11M | -19.99M | -9.87M | -7.73M | 4.43M | -15.56M | 3.46M | -13.28M | -5.62M | -1.16M | -4.51M | -2.05M | -9.87M | -1.01M | 74.00K | -3.43M | -2.05M | 427.77K | -10.89M | -240.00K | -181.43K |
| Income Before Tax | -186.92M | -152.01M | -144.16M | -78.85M | -57.14M | -30.17M | -4.57M | -30.94M | -178.00M | -11.80M | -79.05M | -16.62M | -26.69M | -16.49M | -13.05M | -28.82M | -19.61M | -25.55M | -17.09M | 605.58K | 0.00 | -1.04M | 95.78K |
| Income Before Tax Ratio | -38.76% | -43.32% | -59.27% | -54.43% | -50.38% | -32.90% | -4.50% | -25.73% | -96.07% | -5.70% | -38.61% | -8.47% | -13.50% | -9.61% | -9.87% | -28.45% | -24.51% | -34.52% | -40.38% | 3.40% | 0.00% | -9.16% | 0.69% |
| Income Tax Expense | -277.00K | 140.00K | 164.00K | 145.00K | -239.00K | -1.36M | -34.00K | -4.49M | 681.00K | 1.09M | 3.18M | -1.16M | -4.51M | -2.05M | 243.00K | 468.00K | 590.00K | 270.00K | -3.04M | 96.13K | 833.51K | 4.00K | 3.90K |
| Net Income | -186.64M | -152.15M | -144.33M | -78.99M | -56.90M | -28.98M | -2.29M | -30.32M | -178.68M | -12.88M | -82.23M | -15.46M | -22.18M | -14.36M | -13.29M | -29.29M | -20.20M | -25.82M | -14.05M | 509.45K | -833.51K | -1.04M | 91.88K |
| Net Income Ratio | -38.70% | -43.36% | -59.34% | -54.53% | -50.17% | -31.60% | -2.25% | -25.21% | -96.44% | -6.22% | -40.16% | -7.88% | -11.22% | -8.36% | -10.06% | -28.91% | -25.24% | -34.88% | -33.20% | 2.86% | -7.65% | -9.19% | 0.66% |
| EPS | -1.54 | -1.47 | -1.50 | -1.18 | -1.09 | -0.82 | -0.18 | -3.53 | -21.53 | -1.59 | -10.25 | -2.06 | -3.00 | -2.19 | -3.24 | -7.59 | -6.50 | -11.37 | -9.27 | 0.72 | -1.08 | -1.33 | 0.12 |
| EPS Diluted | -1.54 | -1.47 | -1.50 | -1.18 | -1.09 | -0.82 | -0.17 | -3.53 | -21.53 | -1.58 | -10.25 | -2.06 | -3.00 | -2.19 | -3.24 | -7.59 | -6.50 | -11.37 | -9.27 | 0.60 | -1.08 | -1.33 | 0.12 |
| Weighted Avg Shares Out | 121.24M | 103.37M | 96.20M | 67.02M | 52.23M | 35.32M | 12.79M | 8.58M | 8.30M | 8.11M | 8.02M | 7.52M | 7.40M | 6.55M | 4.11M | 3.86M | 3.11M | 2.27M | 1.52M | 764.91K | 774.84K | 786.00K | 785.90K |
| Weighted Avg Shares Out (Dil) | 121.24M | 103.37M | 96.20M | 67.02M | 52.23M | 35.32M | 13.28M | 8.58M | 8.30M | 8.14M | 8.02M | 7.52M | 7.40M | 6.55M | 4.11M | 3.86M | 3.11M | 2.27M | 1.52M | 801.69K | 774.84K | 786.00K | 792.51K |
ATEC Announces Proposed Public Offering of Common Stock
ATEC Enhances Board with Renowned Spine Prowess
ATEC to Preview the Informatics Sophistication of EOS Catalyst™ at NASS 2023
ATEC Advances Lateral Surgery With Launch of Expandable Technology
ATEC Announces Preliminary Third Quarter 2023 Revenue Results and Raises Full-Year Revenue Guidance
ATEC Clinical Precision and Predictability on Display at NASS 2023
Alphatec: Price Reversal Diverges From Economic Levers That Are Well In Situ (Rating Upgrade)
Alphatec Holdings, Inc. (ATEC) Q2 2023 Earnings Call Transcript
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
ATEC Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance
Source: https://incomestatements.info
Category: Stock Reports